Amerikanische Gesellschaft für Hirudotherapie

National Drug Authority — Uganda

NDA Uganda · Uganda · africa

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Uganda's National Drug Authority — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework or traditional-medicine pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
Uganda
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Ugandan National Drug Policy and Authority Act, Cap 206
  • Ugandan Traditional and Complementary Medicine Act, 2019

Prescriber Requirements

  • Uganda Medical and Dental Practitioners Council–registered physician — order required for any biomedical device application
  • Traditional and complementary medicine practitioners registered under the Traditional and Complementary Medicine Council may have separate scope; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

NDA registration as applicable; English-language labelling. Standard cold-chain conditions.

Import/Export Rules

NDA import authorisation; Ministry of Agriculture, Animal Industry and Fisheries clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. The 2019 Traditional and Complementary Medicine Act offers a possible statutory entry point for hirudotherapy under traditional-practice oversight; this has not been independently confirmed by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.